Abbott's Fourth-Quarter Results: A Prescription for Growth

Abbott Laboratories (NYSE: ABT) has just released its financial results for the fourth quarter of 2025, and the numbers are more than just a routine check-up; they suggest a robust outlook for the company moving forward.

Strong EPS Performance

In a quarter that many analysts were watching closely, Abbott reported a GAAP diluted EPS of $1.01, alongside an adjusted diluted EPS of $1.50. This figure reflects a healthy growth of 12% year-over-year, surpassing the EPS consensus that had analysts buzzing. For the full year, Abbott’s diluted EPS reached $3.72, with an adjusted figure of $5.15, marking a solid 10% increase. Clearly, Abbott is not just walking the tightrope; it's dancing on it.

Revenue Forecast and Sales Growth

Turning to the revenue forecast, Abbott reported a full-year sales figure of $44.3 billion, which translates to a 5.7% increase on a reported basis. When we dig deeper, the organic growth stands at 5.5%, or 6.7% when excluding COVID-19 testing-related sales. The numbers suggest that Abbott is not merely recovering; it is thriving, even as it navigates the post-pandemic landscape.

Looking Ahead: A Bright Horizon

As for 2026, Abbott is projecting organic sales growth between 6.5% to 7.5%, alongside an adjusted diluted EPS forecast of $5.55 to $5.80. This midpoint growth prediction signals that Abbott is not just looking to maintain its health but aims to expand its market share significantly. Given the current trajectory, it seems Abbott has a clear roadmap for success.

Strategic Moves in a Competitive Landscape

In a move that has caught the attention of industry analysts, Abbott announced its intention to acquire Exact Sciences, positioning itself to lead in the burgeoning cancer diagnostics market. The anticipated closing of this deal in Q2 2026 could be a game-changer, allowing Abbott to bolster its portfolio and potentially enhance its earnings surprises in the future.

Innovation and Regulatory Approvals

Abbott is also making waves in the electrophysiology sector, having received FDA approval for its Volt™ PFA System. This innovation, along with the recent CE mark for the TactiFlex™ Duo Ablation Catheter, positions Abbott to capitalize on the growing demand for advanced medical technology. These regulatory approvals not only enhance Abbott’s product offerings but also have the potential to significantly impact future sales and earnings.